I'rom Group Co., Ltd.
Tokyo Stock Exchange 2372.T
I'rom Group Co., Ltd. EBITDA Margin for the year ending March 31, 2024: 18.49%
-
I'rom Group Co., Ltd. EBITDA Margin for the year ending March 31, 2023 was 23.41%, a 17.04% change year over year.
-
I'rom Group Co., Ltd. EBITDA Margin for the year ending March 31, 2022 was 20.00%, a 65.06% change year over year.
-
I'rom Group Co., Ltd. EBITDA Margin for the year ending March 31, 2021 was 12.12%, a -18.29% change year over year.
-
I'rom Group Co., Ltd. EBITDA Margin for the year ending March 31, 2020 was 14.83%, a 9.32% change year over year.
| Date | EBITDA Margin | EBIT Margin | Depreciation and Amortization | EBIT |
|---|
Don’t Miss A Beat
| CEO | Mr. Toyotaka Mori |
| IPO Date | Feb. 1, 2005 |
| Location | Japan |
| Headquarters | Iidabashi Grand Bloom |
| Employees | 1,029 |
| Sector | Health Care |
| Industries | |
I'rom Group Co., Ltd. engages in the advanced medicinal treatment, site management organization, contract research organization, and medical support businesses in Japan. The company engages in the development of medical technologies, such as regenerative medicine and gene therapy for obstructive arteriosclerosis, retinitis pigmentosa, and human immunodeficiency virus infection and acquired immune deficiency syndrome, as well as Sendai virus vector and CytoTune-iPS, a kit for generating iPS cells. It also supports medical institutions in conducting clinical trials; provides clinical trial support services for new drug development and medical equipment for cancer, and rare and intractable diseases; and establishes and operates clinic malls. The company was formerly known as I'Rom Holdings Co., Ltd. and changed its name to I'rom Group Co., Ltd. in July 2015. I'rom Group Co., Ltd. was founded in 1997 and is headquartered in Tokyo, Japan.
Past 5 years
StockViz Staff
January 31, 2025
Any question? Send us an email